<DOC>
	<DOC>NCT00752973</DOC>
	<brief_summary>In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.</brief_summary>
	<brief_title>Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice</brief_title>
	<detailed_description />
	<mesh_term>Lice Infestations</mesh_term>
	<mesh_term>Malathion</mesh_term>
	<criteria>Confirmed active head lice infestation Allergy to pediculicides or hair care products Scalp conditions other than head lice Previous head lice treatment within the past 4 weeks Current antibiotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Head Lice</keyword>
</DOC>